durvalumab

Details

Key Milestones2
Call for patient/clinician input openMay 07, 2025
Call for patient/clinician input closedJune 27, 2025
Submission receivedJune 17, 2025
Submission acceptedJuly 02, 2025
Review initiatedJuly 03, 2025
Draft CADTH review report(s) provided to sponsor for commentSeptember 24, 2025
Deadline for sponsors commentsOctober 06, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorOctober 30, 2025
Expert committee meeting (initial)November 12, 2025
Draft recommendation issued to sponsorNovember 24, 2025
To
November 26, 2025
Draft recommendation posted for stakeholder feedbackDecember 03, 2025
End of feedback periodDecember 17, 2025
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)November 12, 2025

tislelizumab

Details

Key Milestones2
Call for patient/clinician input openApril 28, 2025
Call for patient/clinician input closedJune 20, 2025
Submission receivedJune 09, 2025
Submission acceptedJune 23, 2025
Review initiatedJune 24, 2025
Draft CADTH review report(s) provided to sponsor for commentSeptember 11, 2025
Deadline for sponsors commentsSeptember 22, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorOctober 30, 2025
Expert committee meeting (initial)November 12, 2025
Draft recommendation issued to sponsorNovember 24, 2025
To
November 26, 2025
Draft recommendation posted for stakeholder feedbackDecember 04, 2025
End of feedback periodDecember 18, 2025
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)November 12, 2025

seladelpar

Details

Key Milestones2
Call for patient/clinician input openApril 25, 2025
Call for patient/clinician input closedJune 20, 2025
Submission receivedJuly 10, 2025
Submission acceptedJuly 24, 2025
Review initiatedJuly 25, 2025
Draft CADTH review report(s) provided to sponsor for commentOctober 10, 2025
Deadline for sponsors commentsOctober 22, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorNovember 14, 2025
Expert committee meeting (initial)November 26, 2025
Draft recommendation issued to sponsorDecember 08, 2025
To
December 10, 2025
Draft recommendation posted for stakeholder feedbackDecember 18, 2025
End of feedback periodJanuary 09, 2026
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)November 26, 2025

efgartigimod alfa

Details

Key Milestones2
Call for patient/clinician input openApril 22, 2025
Call for patient/clinician input closedJune 13, 2025
Submission receivedJune 05, 2025
Submission acceptedJune 19, 2025
Review initiatedJune 20, 2025
Draft CADTH review report(s) provided to sponsor for commentSeptember 05, 2025
Deadline for sponsors commentsSeptember 16, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorOctober 09, 2025
Expert committee meeting (initial)October 22, 2025
Draft recommendation issued to sponsorNovember 03, 2025
To
November 05, 2025
Draft recommendation posted for stakeholder feedbackNovember 13, 2025
End of feedback periodNovember 27, 2025
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)October 22, 2025

nivolumab and ipilimumab

Details

Key Milestones2
Call for patient/clinician input open09-Apr-25
Call for patient/clinician input closed03-Jun-25
Submission received22-May-25
Submission accepted05-Jun-25
Review initiated06-Jun-25
Draft CADTH review report(s) provided to sponsor for comment21-Aug-25
Deadline for sponsors comments02-Sep-25
CDA-AMC review report(s) and responses to comments provided to sponsor25-Sep-25
Expert committee meeting (initial)08-Oct-25
Draft recommendation issued to sponsorOctober 21, 2025
To
October 23, 2025
Draft recommendation posted for stakeholder feedback30-Oct-25
End of feedback period14-Nov-25
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)08-Oct-25